Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec 1;60(7):1277-86.
doi: 10.1016/j.toxicon.2012.08.002. Epub 2012 Aug 14.

Epitope mapping of botulinum neurotoxins light chains

Affiliations

Epitope mapping of botulinum neurotoxins light chains

Alexey Zdanovsky et al. Toxicon. .

Abstract

Botulinum neurotoxins (BoNTs) are listed among the most potent biothreat agents. Simultaneously, two out of seven known serotypes of these toxins are used in medicine and cosmetics. This situation calls for development of detailed epitope maps of these toxins. Such maps will help to develop new ways for decreasing damage caused by these toxins if they were to be used as weapons while retaining the therapeutic effect of these toxins used as medicine. Here, we used a library of random fragments of DNA encoding the catalytic domain of botulinum neurotoxin serotype A to identify short epitope-forming sequences. We demonstrated that knowledge of such sequences in a BoNT of one serotype can be used for identification of epitope-forming sequences in other serotypes of BoNTs. We also demonstrated a serodiagnostic value of identified sequences and their ability to retain epitope-specific structures and trigger production of corresponding antibodies, even when they are transferred into a background of a completely alien carrier protein.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Relative location of epitope-forming peptides on the primary structure of light chain of botulinum neurotoxin serotype A
Identified sequences of peptides are highlighted and their names are marked by the bold text. Sequence of light chain of botulinum neurotoxin serotype A is in plain text.
Figure 2
Figure 2. Purification and antigenic properties of RAP-containing hybrid proteins
After purification on Ni-Sepharose, HisbioRAP derivatives were subjected to SDS PAGE and were visualized by staining with Coomassie (A), or were transferred onto a nitrocellulose membrane and treated with either rabbit anti-BoNT/A serum (B) or fraction of rabbit anti-BoNT/A serum, affinity purified on resin containing HisbioRAP-ep4s (C), and followed by treatment with anti-rabbit-horse radish peroxidase conjugate and diamine benzidine. Line 1 contains HisbioRAP-Aep2, 2 - HisbioRAP-Aep1-1, 3 - HisbioRAP, 4 – BoNT/AB-L (a derivative of BoNT/A-L whose C-terminal ep4-containing region is substituted with the corresponding region of BoNT/B-L), 5 - pre-stained molecular weight markers from Invitrogen, Inc., 6 – HisbioRAP-Aep4s, 7 - HisbioRAP-Aep1s, and 8 - HisbioRAP-random peptide.
Figure 3
Figure 3. Relative location of BoNTs sequences used for construction of RAP derivatives on the alignment of sequences of BoNT/A subtypes and BoNT serotypes
Sequences of BoNTs incorporated into RAP derivatives are marked by grey shadow and designated ep1s, ep4s and Zn. Yellow, green and blue colors are used to mark homologous residues, and the dashed lines represent not shown sequences located between two depicted blocks.
Figure 4
Figure 4. Recognition of RAP derivatives containing epitope-forming peptides by antibodies raised to different serotypes of BoNTs
After purification on Ni-Sepharose, HisbioRAP derivatives were subjected to SDS PAGE and were visualized either by staining with Coomassie (A), or were transferred onto a nitrocellulose membrane and treated with rabbit anti-BoNT/F (B), anti-BoNT/B (C), or anti-BoNT/A (D), followed by treatment with anti-rabbit-horse radish peroxidase conjugate and diamine benzidine. Line 1 contains HisbioRAP-A-Zn, 2 - HisbioRAP-FAep1s, 3 - HisbioRAP-BAep1s, 4 - HisbioRAP-Fep1s, 5 - HisbioRAP-Bep1s, 6 - HisbioRAP-Aep1s, 7 –BoNT/AB-L (a BoNT/A-L derivative whose C-terminal region is substituted with the corresponding region of BoNT/B-L), 8 - pre-stained molecular weight markers from Invitrogen, Inc.
Fig. 5
Fig. 5. Specificities of antibodies raised to the hybrid protein carrying three different epitope-forming peptides
Purified proteins were subjected to SDS PAGE and were visualized either by staining with Coomassie (A), or were transferred onto a nitrocellulose membrane and treated with rabbit anti-BoNT/A (B), anti-BoNT/B (C), or sera of mice immunized with α–Tox/FBAep1s (D), followed by the treatment with either donkey anti-rabbit-horse radish peroxidase conjugate (B and C) or goat anti-mice-horse radish peroxidase conjugate (D). Antibodies trapped on the filter were visualized with Metal Enhanced DAB Substrate Kit (Pierce, Inc). Line 1 contains light chain of tetanus toxin, 2 – BoNT/B-L, 3 – BoNT/A-L, 4 – gfp-BoNT/ACH, 5 –HisbioRAP-A-Zn, 6 - HisbioRAP-FBAep1s and 7 - pre-stained molecular weight markers from Fermentas

Similar articles

Cited by

References

    1. Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun. 1997;65:3743–3752. - PMC - PubMed
    1. Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine. 2002;20:1640–1648. - PubMed
    1. Atassi MZ. Basic immunological aspects of botulinum toxin therapy. Mov Disord. 2004;19(Suppl 8):S68–84. - PubMed
    1. Atassi MZ, Dolimbek BZ, Hayakari M, Middlebrook JL, Whitney B, Oshima M. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855–1296 with antitoxin antibodies from three host species. J Protein Chem. 1996;15:691–700. - PubMed
    1. Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology. 2011;216:782–792. - PubMed

Publication types

Substances